DIABETES CIES SEARCH ENGINE [SELECTED WEBSITES]

Blog Archive

Wednesday, August 15, 2007

CombinatoRx CRx-401 for Type 2 Diabetes

A novel insulin sensitizer designed to provide anti-diabetic activity without promoting weight gain : CombinatoRx (NASDAQ: CRXX) Announces Initiation of Phase 2a Proof-of-Concept Clinical Study with CRx-401 for Type 2 Diabetes... link to the CombinatoRx's Press Release.